Lifetime risk for developing congestive heart failure: The Framingham Heart Study

Circulation

Volumn 106, Issue 24, 2002, Pages 3068-3072

  Lloyd Jones, Donald M ^a,b,d   Larson, Martin G ^a,b   Leip, Eric P ^c   Beiser, Alexa ^c   D'Agostino, Ralph B ^b,c   Kannel, William B ^a,b   Murabito, Joanne M ^a,b   Vasan, Ramachandran S ^a,b   Benjamin, Emelia J ^a,b   Levy, Daniel ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^d FRAMINGHAM HEART STUDY   (United States)

Author keywords

Heart failure; Hypertension; Myocardial infarction; Risk factors

Indexed keywords

ADULT; AGE; AGING; ARTICLE; CONGESTIVE HEART FAILURE; FEMALE; HEART INFARCTION; HUMAN; HYPERTENSION; INCIDENCE; LIFESPAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; UNITED STATES;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; BLOOD PRESSURE; COHORT STUDIES; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; MALE; MASSACHUSETTS; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK ASSESSMENT; RISK FACTORS; SEX DISTRIBUTION;

EID: 0037058826     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000039105.49749.6F     Document Type: Article

References (19)

1. American Heart Association. 2002 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association: 2001.
2. Braunwald E. Shattuck Lecture: Cardiovascular medicine at the turn of the millennium: Triumphs, concerns, and opportunities. N Engl J Med. 1997; 337:1360-1369.
3. Dawber TR, Kannel WB, Lyell LP. An approach to longitudinal studies in a community: The Framingham study. Ann N Y Acad Sci. 1963;107: 539-556.
4. Kannel WB, Feinleib M, McNamara PM, et al. An investigation of coronary heart disease in families: The Framingham offspring study. Am J Epidemiol. 1979;110:281-290.
5. Abbott RD, McGee DL. The Framingham Study: An Epidemiological Investigation of Cardiovascular Disease. Section 37. Bethesda, MD: National Heart, Lung, and Blood Institute. 1987.
6. Kannel WB, D'Agostino RB, Silbershatz H, et al. Profile for estimating risk of heart failure. Arch Intern Med. 1999;159:1197-1204.
7. SAS Institute. SAS/STAT Software: Changes and Enhancements Through Release 6.11. Cary, NC: SAS Institute, Inc; 1996.
8. Lloyd-Jones DM, Larson MG, Beiser A, et al. Lifetime risk of developing coronary heart disease. Lancet. 1999;353:89-92.
9. Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men. JAMA. 2002; 287:1003-1010.
10. Vasan RS, Larson MG, Benjamin EJ, et al. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction. J Am Coll Cardiol. 1999;33:1948-1955.
11. Levy D, Larson MG, Vasan RS. et al. The progression from hypertension to congestive heart failure. JAMA. 1996;275:1557-1562.
12. Feuer EJ, Wung L, Boring CC, et al. The lifetime risk of developing breast cancer. J Natl Cancer Inst. 1993;85:892-897.
13. Cummings SR, Black DM, Rubin SM. Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med. 1989;149:2445-2448.
14. Goldberg RJ, Konstam MA. Assessing the population burden from heart failure: Need for sentinel population-based surveillance systems. Arch Intern Med. 1999;159:15-17.
15. Senni M, Triboiuilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community: A study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation. 1998;98:2282-2289.
16. Senni M. Triboiuilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community: Trends in incidence and survival in a 10-year period. Arch Intern Med. 1999;159:29-34.
17. Lloyd-Jones DM, Martin DO, Larson MG, et al. Accuracy of death certificates for coding coronary heart disease as the cause of death. Ann Intern Med. 1998;129:1020-1026.
18. Kostis JB, Davis BR, Cutler J, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA. 1997;278:212-216.
19. Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol. 1996;27:1214-1218.